CJ
TNXP icon

Caitlin John’s Tonix Pharmaceuticals TNXP Stock Holding History

Caitlin John’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06K Hold
77
– – ﹤0.01% 792
2025
Q4 		$1.2K Buy
+77
New +$1.42K ﹤0.01% 773

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Caitlin John's TNXP Position: Q1 2026 in Review

Caitlin John held its Tonix Pharmaceuticals (TNXP) position steady in Q1 2026 at 77 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #792.

Caitlin John first reported a position in TNXP in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.2K in Q4 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Caitlin John held 77 shares of Tonix Pharmaceuticals worth $1.06K as of Q1 2026.
  • Caitlin John left its Tonix Pharmaceuticals share count unchanged in Q1 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #792 holding.
  • Caitlin John first reported a position in Tonix Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Caitlin John's Tonix Pharmaceuticals position peaked at $1.2K in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.